Continuing its diversification strategy, Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals in exchange for US$1.44 B. The deal gives Alexion access to Andexxa® (andexanet alfa), the first and only approved Factor Xa inhibitor reversal agent on the market, as well as Bevyxxxa® (betrixaban), an oral anticoagulant for certain patient types which gained US approval in June 2017, and Phase II asset cerdulatinib. Investors have raised concerns regarding the deal given that Andexxa has struggled to capture market share in the anticoagulant segment amid manufacturing and hospital access issues.